Intended use: For determination of resistance to activated Protein C, caused by the Factor V:Q506 (Factor V Leiden) mutation, in plasma from untreated individuals and from patients on Heparin or Oral Anticoagulant Therapy (OAT).
Principle: Based on performing the Activated Partial Thromboplastin Time (APTT)-based APC-resistance assay in the presence of excess Factor V Reagent Plasma, the sensitivity and specificity for the Factor V:Q506 Mutation is significantly increased.
Vials and volumes:
- 2 x 4 mL APTT reagent (liq)
- 2 x 4 mL Factor V Reagent Plasma (lyo)
- 2 x 2 mL APC/CaCl2 (lyo)
- 2 x 2 mL CaCl2 (liq)
- 2 x 1 mL APC Control Plasma Level 1 (lyo)
- 2 x 1 mL APC Control Plasma Level 2 (lyo)
*ACL, ACL TOP, and HemosIL are trademarks of Instrumentation Laboratory. APC is a trademark of Chromogenix AB.
Life Science Research
